Cargando…

Hypocalcemia in a Patient With Metastatic Prostate Cancer From Denosumab Treatment

Denosumab is a humanized monoclonal antibody that binds RANKL to inhibit osteoclast activity. It is indicated for the prevention of skeletal-related events (SRE) in patients with solid tumors who have bone metastasis and in patients with multiple myeloma. Hypocalcemia is one of the known side effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Gouli, Sugam, Wang, Jimmy, Patel, Anush, Allerton, Jeffery
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8427738/
https://www.ncbi.nlm.nih.gov/pubmed/34522524
http://dx.doi.org/10.7759/cureus.17046

Ejemplares similares